Genentech

Mytrus appoints Anthony Costello as CEO

Friday, July 6, 2012 01:33 PM

Mytrus, a San Francisco-based clinical technology and services company for medical and pharmaceutical research, has appointed Anthony J. Costello as CEO. He

More... »

Roche to streamline R&D activities, close New Jersey site

Wednesday, June 27, 2012 10:46 AM

Roche has decided to consolidate activities within its research and early development division, resulting in the closure of the company’s Nutley, N.J., site. Research and development activities will be consolidated at the existing sites in Germany and Switzerland, focusing on oncology, virology, metabolism and neuroscience.

More... »

AC Immune, Genentech form second antibody collaboration for Alzheimer's

Monday, June 18, 2012 03:03 PM

Swiss-based biopharmaceutical company AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group, for research, development and commercialization of AC Immune's anti-Tau antibodies for the potential treatment of Alzheimer's disease and other neurodegenerative diseases.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

FDA approves Erivedge to treat skin cancer

Monday, January 30, 2012 04:02 PM

Genentech’s Erivedge (vismodegib) has been approved by the FDA to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).

More... »

Roche, Xenon ink $646 million pain pact

Friday, January 13, 2012 12:15 PM

Roche’s Genentech unit plans to discover compounds and diagnostics for treatment of pain by collaborating with Xenon Pharmaceuticals, based in Vancouver.

More... »

Garland joins Exelixis

Tuesday, October 25, 2011 12:52 PM

Exelixis has named J. Scott Garland as executive vice president and chief commercial officer. As the company's chief commercial officer, Gardland will oversee the commercial functions of marketing, sales and commercial operations, and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications.

More... »

Report: U.S. medical innovation at risk without funding

Thursday, October 6, 2011 12:03 PM

U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investment away from the United States towards Europe and Asia, according to a report by the National Venture Capital Association'sMedIC Coalition.

More... »

Array signs $685 million agreement with Genentech

Tuesday, August 9, 2011 12:08 PM

Array BioPharma has signed an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule checkpoint kinase 1 (ChK-1) program. The programs include Genentech's compound GDC-0425 (RG7602), currently in phase I, and Array's compound ARRY-575, which is being prepared for an investigational new drug application to initiate a phase I trial in cancer patients.

More... »

Positive results for Curis phase II trial

Tuesday, March 29, 2011 12:46 PM

Curis, a drug development company focusing on next-generation targeted small molecule drug candidates for cancer treatment, announced a positive outcome from a pivotal phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly-owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

More... »